A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer

OBJECTIVE: Anlotinib, an oral small-molecular tyrosine kinase inhibitor (TKI) on tumor angiogenesis and growth, has a wide spectrum of inhibitory effects on targets such as vascular endothelial growth factor receptors 2/3 (VEGFR2/3), etc. The efficacy and safety of anlotinib in the treatment of plat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Qingli, Hu, Yanhui, Ma, Dongyang, Liu, Huaimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850384/
https://www.ncbi.nlm.nih.gov/pubmed/33536747
http://dx.doi.org/10.2147/DDDT.S286529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850384/
https://www.ncbi.nlm.nih.gov/pubmed/33536747
http://dx.doi.org/10.2147/DDDT.S286529

Ejemplares similares